+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy



Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy



Transfusion 54(12): 3036-3042



Transfusion-related acute lung injury (TRALI) is known as a life-threatening complication of transfusion. HLA and HNA antibodies have been associated with the immune pathway of TRALI. Since donors with a history of transfusion and/or pregnancy are presumed to have an increased risk of carrying such antibodies, we investigated the association of a history of transfusion or pregnancy with the occurrence of HLA alloimmunization in our donor population. A total of 1018 female plateletpheresis donors and male plateletpheresis donors with a history of transfusion were enrolled in the study. Included donors were systematically screened, using Luminex technology, for anti-HLA Class I and II. The association of donor history with HLA alloimmunization status was analyzed. The overall alloimmunization rate was 20.2%. In 0.0% of the nulliparous transfused female donors and in 1.3% of the transfused male donors, anti-HLA were detected. Thirty-one percent of the parous women versus 4.2% of the nulliparous women screened positive for anti-HLA. The rate of HLA alloimmunization increased with parity. Our data indicate that a history of transfusion is a minor risk factor for immunization against HLA antigens. In contrast, former pregnancies constitute a major risk factor for the development of HLA antibodies. Since HLA alloimmunization rate increases with parity, TRALI risk reduction measures should focus on this particular donor population. Repeated testing of female plateletpheresis donors after each pregnancy is implemented in our blood service.

(PDF emailed within 0-6 h: $19.90)

Accession: 055670786

Download citation: RISBibTeXText

PMID: 24863861

DOI: 10.1111/trf.12727


Related references

Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome. Transfusion 51(3): 504-510, 2011

A comparison of two robotic platforms to screen plateletpheresis donors for HLA antibodies as part of a transfusion-related acute lung injury mitigation strategy. Transfusion 50(8): 1766-1777, 2010

A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. Transfusion 51(1): 92-96, 2011

Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion 48(12): 2549-2558, 2008

Frequency of adverse events in plateletpheresis donors in regional transfusion centre in North India. Transfusion and Apheresis Science 49(2): 244-248, 2014

Efficacy of platelet transfusion in patients with acute leukemia and laboratory evaluation of normal donors undergoing plateletpheresis using blood cell separator hemonetics. Japanese Journal of Medicine 17(1): 100, 1978

Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors prior to screening. The Transfusion Safety Study/NHLBI Donor Repository. Transfusion 29(7): 572-580, 1989

Screening of blood donors and recipients for Borrelia burgdorferi antibodies: no evidence of B. burgdorferi infection transmitted by transfusion. Infusionstherapie und Transfusionsmedizin 19(4): 204-207, 1992

Repeat whole-blood and plateletpheresis donors:unreported deferrable risks, reactive screening tests, andresponse to incentive programs. Transfusion 41(6): 736-743, 2001

Efficacy of Screening Donors for Antibodies to the Hepatitis C Virus to Prevent Transfusion-Associated Hepatitis: Final Report of a Prospective Trial. Hepatology 22(2): 439-445, 1995

Efficacy of blood screening of donors for antibodies to hepatitis C virus in preventing post-transfusion nonA, nonB hepatitis. Journal of Public Health Medicine 15(4): 367, 1993

Donors whose blood reacts falsely positive in transfusion microbiology screening assays need not be lost to transfusion. Transfusion Medicine 17(1): 55-59, 2007

The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 49(9): 1825-1835, 2009

Strategies to recruit plateletpheresis donors from a registry of HLA-typed, unrelated bone marrow donors. Transfusion (Bethesda) 33(8): 675-678, 1993